Literature DB >> 35075696

No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance.

Adenrele Gleason1, Nahid Tayebi1, Grisel Lopez1, Ellen Sidransky1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35075696      PMCID： PMC8940713          DOI： 10.1002/mds.28935

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   9.698


× No keyword cloud information.
  4 in total

Review 1.  GBA mutations, glucosylceramide and Parkinson's disease.

Authors:  Ivan Milenkovic; Shani Blumenreich; Anthony H Futerman
Journal:  Curr Opin Neurobiol       Date:  2021-12-06       Impact factor: 6.627

2.  Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.

Authors:  Matthew Surface; Manisha Balwani; Cheryl Waters; Alexander Haimovich; Ziv Gan-Or; Karen S Marder; Tammy Hsieh; Linxia Song; Shalini Padmanabhan; Frank Hsieh; Kalpana M Merchant; Roy N Alcalay
Journal:  Mov Disord       Date:  2021-11-06       Impact factor: 9.698

3.  Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients.

Authors:  Arndt Rolfs; Anne-Katrin Giese; Ulrike Grittner; Daniel Mascher; Deborah Elstein; Ari Zimran; Tobias Böttcher; Jan Lukas; Rayk Hübner; Uta Gölnitz; Anja Röhle; Ales Dudesek; Wolfgang Meyer; Matthias Wittstock; Hermann Mascher
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

4.  Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review.

Authors:  Shoshana Revel-Vilk; Maria Fuller; Ari Zimran
Journal:  Int J Mol Sci       Date:  2020-09-28       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.